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ABSTRACT
Introduction: The aim of this study was to evaluate the
efﬁcacy of pemetrexed and platinum plus pembrolizumab
by baseline tumor burden.
Methods: A total of 616 patients in the intention-totreat population of the KEYNOTE-189 study were
included in this analysis. Baseline tumor burden subgroups were identiﬁed on the basis of extent of distant
metastasis (M1a versus M1b), median number (3
versus >3) of organ systems with lesions, or symptom
severity score of patient-reported lung cancer-associated
symptoms (median versus >median). Overall survival
(OS), progression-free survival (PFS), and PFS-2 were
evaluated by Kaplan-Meier and univariate Cox methods.
Objective response rate was analyzed using logistic
regression models, and duration of response was
analyzed descriptively. Efﬁcacy outcomes were also
analyzed according to the programmed death-ligand 1
expression levels.
Results: OS and PFS were signiﬁcantly improved with
pemetrexed and platinum plus pembrolizumab in all baseline tumor burden subgroups (M1a stage: OS hazard ratio
[HR] ¼ 0.54, p ¼ 0.0037; PFS HR ¼ 0.48, p ¼ 0.0001; M1b
stage: OS HR ¼ 0.58, p  0.0001; PFS HR ¼ 0.51, p 
0.0001; number of organ systems with lesion  3: OS HR ¼
0.49, p  0.0001 PFS HR ¼ 0.41, p  0.0001; >3: OS HR ¼
0.67, p ¼ 0.0068; PFS HR ¼ 0.59, p ¼ 0.0001; symptom
severity score  median: HR ¼ 0.51, p  0.0001; PFS HR
0.49, p  0.0001; > median: OS HR ¼ 0.60, p ¼ 0.0003; PFS
HR ¼ 0.48, p  0.0001). PFS2 and objective response rate
were also improved with pemetrexed and platinum plus
pembrolizumab in all baseline tumor burden subgroups.

Efﬁcacy outcomes were generally consistent regardless of
programmed death-ligand 1 expression levels.
Conclusions: Pemetrexed and platinum plus pembrolizumab were found to have relevant efﬁcacy regardless
of the extent of baseline tumor burden and the variables
used to deﬁne it. These results further support pemetrexed
and platinum plus pembrolizumab as the standard of care
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Introduction
The recent advent of immune checkpoint inhibitors
(ICIs), alone or in combination with chemotherapy,1 has
greatly reduced the risk of disease progression and
improved survival in treatment-naive patients with
metastatic nonsquamous NSCLC (NSQ-NSCLC).2–6
Pemetrexed has been the standard of care in combination with platinum-based chemotherapy for the
treatment of patients with advanced NSQ-NSCLC for
more than a decade.7–9 In 2017, the U.S. Food and Drug
Administration approved pemetrexed and platinum in
combination with pembrolizumab as a ﬁrst-line treatment of metastatic NSQ-NSCLC, on the basis of the
objective response rate (ORR) of the cohort G of the
phase 2 KEYNOTE-021 study.10,11 The efﬁcacy and the
manageable safety proﬁle of pemetrexed and platinum
in combination with pembrolizumab were subsequently conﬁrmed in the phase 3 KEYNOTE-189
study.12 After a median follow-up of 10.5 months,
pemetrexed and platinum plus pembrolizumab significantly improved overall survival (OS) and
progression-free survival (PFS), compared with pemetrexed and platinum plus placebo.12 The improvement
in OS, PFS, and ORR with pemetrexed and platinum
plus pembrolizumab was observed irrespectively of
tumor programmed death-ligand 1 (PD-L1) expression
levels.13,14 Importantly, efﬁcacy beneﬁts were consistently maintained at a longer follow-up of approximately 4 years.2 The effectiveness of pemetrexed and
platinum plus pembrolizumab in the ﬁrst-line treatment of patients with NSQ-NSCLC has also been
revealed in the real-world clinical setting, with results
comparable with those of the KEYNOTE-189 trial.15
Baseline tumor burden generally deﬁned by tumor
volume, tumor diameter, location, or number of metastatic lesions16 is being increasingly recognized as an
important determinant of clinical outcomes and treatment decisions.16–20 The presence of high tumor burden
at baseline is considered a negative prognostic factor in
various cancer types, including metastatic NSCLC.16,21–23
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Preclinical studies24 and emerging clinical evidence also
indicate that the extent of tumor burden at baseline inﬂuences treatment responses and outcomes to ICI
monotherapy in advanced NSCLC.18,24
Results from the KEYNOTE-189 study revealed a
similar improvement in PFS and OS by pemetrexed and
platinum plus pembrolizumab in patients with poor
prognostic factors, including presence of brain metastases, liver metastases, and M1b stage.13,14 Data on the
impact of baseline tumor burden to treatment with
pemetrexed and platinum plus pembrolizumab are
lacking. The aim of this post hoc analysis was to evaluate
the efﬁcacy beneﬁt of pemetrexed and platinum plus
pembrolizumab by baseline tumor burden.

Materials and Methods
Study Design
KEYNOTE-189 (NCT02578680) study design, eligibility criteria, and patient baseline and demographic
characteristics have been previously reported12 and are
brieﬂy summarized in the Supplementary Materials. The
trial protocol and all amendments were approved by the
appropriate ethics panel at each study center. The trial
was conducted in accordance with the Declaration of
Helsinki and was overseen by an external monitoring
committee. All patients provided informed written consent before enrollment.

Patients
The intention-to-treat population included 616 patients, randomized to pemetrexed and platinum plus
pembrolizumab (n ¼ 410) or pemetrexed and platinum
plus placebo (n ¼ 206).13 All patients in the intention-totreat population were included in this analysis. All patients provided written informed consent before enrollment. The results reported herein are from the data
cutoff date of May 20, 2019. Median time from
randomization to data cutoff was 31 months (26.5–38.8
mo).14

Outcomes
Efﬁcacy end points included OS, PFS, PFS-2, ORR, and
duration of response (DoR).

Tumor Burden at Baseline
We used three distinct variables to deﬁne tumor
burden at baseline.
Extent of Distant Metastases. The KEYNOTE-189 study
enrolled patients with histologically or cytologically
conﬁrmed diagnosis of stage IV M1a or M1b NSQNSCLC,12 according to the TNM classiﬁcation system
seventh edition.25 Stage M1a deﬁnes patients with
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intrathoracic metastases only (lesions in the contralateral lobe or pleura or pleural/pericardial effusion),
whereas stage M1b indicates the presence of extrathoracic metastases.26 Thus, in this post hoc analysis, we
used the degree of metastatic involvement, deﬁned by
the M1a and M1b staging, as a measure of baseline tumor burden. We categorized patients into two distinct
baseline tumor burden subgroups: patients with low
tumor burden (stage M1a) and patients with high tumor
burden (stage M1b).
Number of Organ Systems With Lesions. Evaluation of
the number of organ systems with lesions was based on
the imaging assessment at the time of randomization and
was used as a second variable. Organ systems included
in the baseline tumor burden assessment are listed in
Supplementary Table 1. Lesions were identiﬁed at
baseline, and each lesion was mapped onto organ systems. Each organ system was counted regardless of the
number of lesions present. The median number of organ
systems with lesions (n ¼ 3) was used as a cutoff value
to categorize patients in two subgroups: patients with
median number of organ system with lesions less than or
equal to 3 (low tumor burden) and patients with median
number of organ systems with lesions of greater than 3
(high tumor burden).
Patient-Reported Lung Cancer-Associated Symptoms
(Symptom Severity Score). Quality of life and patientreported outcomes from the KEYNOTE-189 study have
been previously reported27 using the European Organisation for Research and Treatment of Cancer (EORTC)
Quality of Life Questionnaire Core 30,28 Quality of Life
Questionnaire Lung Cancer 13 (QLQ-LC13),29 and EuroQoL 5D.28 In this study, the patient population with
available baseline QLQ-LC13 assessment included 357
patients in the pemetrexed and platinum plus pembrolizumab arm and 179 in the pemetrexed and platinum
plus placebo arm. The symptom severity score was
derived from six questions assessing lung cancerassociated symptoms from the patient-reported QLQLC13 instrument (coughing, dyspnea, hemoptysis, pain in
arm or shoulder, pain in the chest, pain in other parts of
body) administered at baseline (cycle 1). The patient
scoring of symptoms was translated into a numeric rating
for each of the six symptoms and added up to a total score,
which was standardized to a scale ranging from 0 (absence
of symptom) to 100 (maximum symptom) by linear
transformation. The median score (n ¼ 122.2) was used as
a cutoff value to categorize patients in two subgroups:
patients with symptom severity score less than or equal to
median (low tumor burden) and patient with symptom
severity score greater than median (high tumor burden).
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Statistical Analysis
Cohorts of interest for statistical analysis were
deﬁned by the three variables used to deﬁne tumor
burden. Descriptive, within-treatment arm, and withincohort summary statistics for OS, PFS, and PFS-2 were
derived using the Kaplan-Meier method. Within each
cohort, between-treatment arm comparative hazard ratio (HR) estimates for OS, PFS, and PFS-2 were obtained
using univariate stratiﬁed Cox models; the stratiﬁcation
variables were the original stratiﬁcation variables of the
KEYNOTE-189 study (PD-L1 expression, choice of
platinum-based drug, and smoking history). ORR was
analyzed using logistic regression models. DoR was
analyzed using the Kaplan–Meier method for withintreatment arm, within-cohort descriptive summaries.
Analyses by PD-L1 expression levels (tumor proportion
score [TPS] <1% and 1%) within each baseline tumor
burden subgroup were also performed.

Results
Patients
Baseline Tumor Burden Subgroups. Figure 1 reveals
the population analysis and the categorization of baseline tumor burden subgroups. The proportion of patients
with M1a or M1b stage, number of organ systems with
lesions less than or equal to 3 or greater than 3, or a
symptom severity score less than or equal to median or
greater than median was balanced across the two
treatment arms. Nevertheless, both treatment arms had
a higher number of patients with M1b stage (69.5%
versus 73.8%) than with M1a stage (30% versus 25.7%),
with less than or equal to 3 organ system with lesions
(57.3% versus 57.3%) than with greater than 3 organ
systems with lesions (42.7% versus 42.7%), and with
symptom severity score greater than median (45.6%
versus 47.1%) than with symptom severity score less
than or equal to median (41.5% versus 39.8%) (Fig. 1).
Baseline Demographic and Disease Characteristics.
Baseline demographic and disease characteristics were
generally balanced across subgroups (Supplementary
Tables 2–4). An increased proportion of older patients (aged 65 y) was present in the pemetrexed and
platinum plus pembrolizumab arm compared with the
pemetrexed and platinum plus placebo arm of the
following tumor burden subgroups: M1b stage (50.2%
versus 38.2%), greater than 3 organ systems with lesions (49.1% versus 34.1%), and symptom severity
score less than or equal to median (57.6% versus
46.3%). In addition, the proportion of patients with
Eastern Cooperative Oncology Group performance
status (ECOG PS) 1 was higher in both treatment arms
of the subgroups with M1b stage, greater than 3 organ
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Figure 1. Identiﬁcation of the analysis population and characterization of baseline tumor burden subgroups. aThere were two
patients with missing data in the treatment arm and one patient in the control arm. bMedian number of organ systems with
lesions was 3. cMedian score ¼ 122.2, on the basis of six lung-speciﬁc symptoms from the patient-reported QLQ-LC-13 instrument (coughing, dyspnea, hemoptysis, pain in arm or shoulder, pain in the chest, pain in other parts of body); the number
of patients with available lung cancer-associated symptoms at baseline from the QLQ-LC13 instrument was 357 in the
pemetrexed þ platinum þ pembrolizumab arm and 179 in the pemetrexed þ platinum þ placebo arm. dPercentage calculations are provided on the basis of total patient population (n ¼ 410 and N ¼ 206) and not total number of patients with
available lung cancer-associated symptoms at baseline from the QLQ-LC13 instrument. QLC-LC13, Quality of Life Questionnaire Lung Cancer 13.

systems with lesions, and symptom severity score >
median versus those with M1a stage, less than or equal
to 3 organ system with lesions, and symptom severity
score less than or equal to median (Supplementary
Tables 2–4).

OS and PFS by Baseline Tumor Burden
In the subgroup with M1a stage, median OS was
29.3 months with pemetrexed and platinum plus
pembrolizumab and 19.5 months with pemetrexed and
platinum plus placebo (HR ¼ 0.54, 95% conﬁdence
interval [CI]: 0.35–0.82, p ¼ 0.0037) (Fig. 2A). In the
subgroup with M1b stage, median OS was 19.1 months
with pemetrexed and platinum plus pembrolizumab
and 8.9 months with pemetrexed and platinum plus
placebo (HR ¼ 0.58, 95% CI: 0.4–0.73, p  0.0001)
(Fig. 2C). PFS was also signiﬁcantly improved with
pemetrexed and platinum plus pembrolizumab in both
M1a and M1b stages. In the subgroup with M1a stage,
median PFS was 14.0 month with pemetrexed and
platinum plus pembrolizumab and 7.6 months with
pemetrexed and platinum plus placebo (HR ¼ 0.48,
95% CI: 0.32–0.70, p ¼ 0.0001) (Fig. 2B). In the
subgroup with M1b stage, median PFS was 7.6 months
with pemetrexed and platinum plus pembrolizumab
and 4.7 months with pemetrexed and platinum plus
placebo (HR ¼ 0.51, 95% CI: 0.41–0.63, p  0.0001)
(Fig. 2D). Estimated OS and PFS rates at 12 months
and 24 months were higher with pemetrexed and
platinum plus pembrolizumab than with pemetrexed
and platinum plus placebo in both M1a and M1b
subgroups (Fig. 2).

A signiﬁcant improvement in OS with pemetrexed
and platinum plus pembrolizumab compared with the
pemetrexed and platinum plus placebo arm was also
observed when tumor burden was assessed by the
number of organ systems with lesions. In the subgroup
with less than or equal to 3 organ systems with lesions,
median OS was 27.2 months with pemetrexed and
platinum plus pembrolizumab combination and 13.5
months with pemetrexed and platinum plus placebo
(HR ¼ 0.49, 95% CI: 0.37–0.64, p  0.0001) (Fig. 3A). In
the subgroup with greater than 3 organ systems with
lesions, median OS was 13.5 months with pemetrexed
and platinum plus pembrolizumab and 7.6 months with
pemetrexed and platinum plus placebo (HR ¼ 0.67, 95%
CI: 0.50–0.90, p ¼ 0.0068) (Fig. 3C). Median PFS was
11.2 months with pemetrexed and platinum plus pembrolizumab and 6.0 months with pemetrexed and platinum plus placebo (HR ¼ 0.41, 95% CI: 0.31–0.52, p 
0.0001) in the subgroup of patients with less than or
equal to 3 organ systems with lesions (Fig. 3B). In patients with greater than 3 organ systems with lesions,
median PFS was 6.2 months in the pemetrexed and
platinum plus pembrolizumab arm and 4.6 months in the
pemetrexed and platinum plus placebo arm (HR ¼ 0.59,
95% CI: 0.45–0.78, p ¼ 0.0001) (Fig. 3D). Estimated OS
and PFS rates at 12 months and 24 months were
improved with pemetrexed and platinum plus pembrolizumab compared with pemetrexed and platinum
plus placebo across both subgroups (Fig. 3).
Treatment with pemetrexed and platinum plus
pembrolizumab signiﬁcantly improved median OS in the
subgroup with symptom severity score less than or
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Figure 2. OS and PFS by M1a and M1b staging. Illustrated are Kaplan-Meier estimates of OS and PFS in patients with M1a stage
NSQ-NSCLC (A and B) or M1b stage NSQ-NSCLC (C and D). Tick marks indicate censoring of data at the last time the patient
was known to be alive. CI, conﬁdence interval; HR, hazard ratio; NSQ-NSCLC, nonsquamous NSCLC; OS, overall survival; Pem,
pemetrexed; Pembro, pembrolizumab; PFS, progression-free survival; Plat, platinum.

equal to median compared with pemetrexed and platinum plus placebo (25.8 mo versus 13.2 mo; HR ¼ 0.51,
95% CI: 0.36–0.71; p  0.0001) (Fig. 4A). A similar
improvement was observed in the subgroup with
symptom severity score greater than median with
pemetrexed and platinum plus pembrolizumab
compared with pemetrexed and platinum plus placebo
(17.0 mo versus 8.9 mo; HR ¼ 0.60, 95% CI: 0.45–0.79,
p ¼ 0.0003) (Fig. 4C). In addition to the improvement in
OS, median PFS was signiﬁcantly longer in the subgroup
with symptom severity score less than or equal to median treated with pemetrexed and platinum plus pembrolizumab compared with pemetrexed and platinum
plus placebo (9.9 mo versus 5.2 mo; HR ¼ 0.49, 95% CI:
0.36–0.66, p  0.0001) (Fig. 4B). Similarly, in patients
with symptom severity score > median, median PFS was
7.9 months in the pemetrexed and platinum plus pembrolizumab arm and 4.8 months in the pemetrexed and
platinum plus placebo arm (HR ¼ 0.48, 95% CI: 0.36–
0.62, p  0.0001) (Fig. 4D). The estimated OS and PFS
rates at 12 and 24 months were higher in the pemetrexed and platinum plus pembrolizumab arm compared
with the pemetrexed and platinum plus placebo arm
across both subgroups (Fig. 4).
In the primary analysis of the KEYNOTE-189 study, the
superior efﬁcacy of pemetrexed and platinum plus

pembrolizumab was maintained regardless of tumor PDL1 expression levels.12 Similarly, in this post hoc analysis,
OS and PFS were improved with pemetrexed and platinum
plus pembrolizumab in PD-L1–negative (TPS < 1%) and in
PD-L1–positive (TPS  1%) patients across all baseline
tumor burden subgroups (Supplementary Tables 5–6).

ORR and Median DoR by Baseline Tumor Burden
ORR with pemetrexed and platinum plus pembrolizumab was 55.6% in the subgroup with M1a stage
and 49.8% in the M1b stage subgroup, compared with
32% and 19.1% with pemetrexed and platinum plus
placebo, respectively (Fig. 5A). DoR also favored pemetrexed and platinum plus pembrolizumab compared
with pemetrexed and platinum plus placebo in M1a
stage (16.7 mo versus 9.7 mo) and in M1b stage (10.8
mo versus 7.1 mo) subgroups (Fig. 5B). A similar
improvement in ORR and DoR was observed with
pemetrexed and platinum plus pembrolizumab
compared with pemetrexed and platinum plus placebo
in the tumor burden subgroups with less than or equal
to 3 organ systems with lesions (60.0% versus 20.0%;
13.6 mo versus 7.7 mo) and greater than 3 organ systems with lesions (39.6% versus 26.8%; 12.1 mo versus
6.9 mo) (Fig. 5A and B). Similarly, the proportion of
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Figure 3. OS and PFS by number of organ systems with lesion. Illustrated are Kaplan-Meier estimates of OS and PFS in patients
with less than or equal to 3 organ systems with lesions (A and B) or greater than 3 organ systems with lesions (C and D). Tick
marks indicate censoring of data at the last time the patient was known to be alive. CI, conﬁdence interval; HR, hazard ratio;
NSQ-NSCLC, nonsquamous NSCLC; OS, overall survival; Pem, pemetrexed; Pembro, pembrolizumab; PFS, progression-free
survival; Plat, platinum.

patients who experienced an ORR and longer DoR was
higher with pemetrexed and platinum plus pembrolizumab than with pemetrexed and platinum plus
placebo in the subgroup with symptom severity score
less than or equal to median (52.1% versus 28.6%; 13.7
mo versus 8.3 mo) and greater than median (49.1%
versus 19.3%; 10.3 mo versus 6.7 mo) (Fig. 5A and B).
The ORR and DoR beneﬁts with pemetrexed and platinum plus pembrolizumab were also maintained across
all baseline tumor burden subgroups irrespectively of
PD-L1 expression levels (Supplementary Table 7), except
for a shorter DoR with pemetrexed and platinum plus
pembrolizumab in the subgroup with greater than 3
organ systems with lesion and PD-L1 TPS less than 1%
(Supplementary Table 7). The lack of difference in DoR
beneﬁt between the treatment arms in this subgroup of
patients is likely due to the small sample size
(Supplementary Table 7).

PFS-2 by Baseline Tumor Burden
In the primary analysis of the KEYNOTE-189 study,
treatment with pemetrexed and platinum plus pembrolizumab resulted in an improvement of median PFS-2

compared with pemetrexed and platinum plus placebo
(17.0 mo versus 9.0 mo).13 In the present analysis, the
PFS-2 beneﬁt of pemetrexed and platinum plus pembrolizumab was maintained across all baseline tumor
burden subgroups. In the subgroup with M1a stage,
median PFS-2 was 23.0 months with pemetrexed and
platinum plus pembrolizumab and 15.0 months with
pemetrexed and platinum plus placebo (HR ¼ 0.57, 95%
CI: 0.38–0.86, p ¼ 0.0059) (Table 1). Similar improvement was observed with pemetrexed and platinum plus
pembrolizumab compared with pemetrexed and platinum plus placebo in patients with M1b stage (median
15.1 mo versus 7.6 mo [HR ¼ 0.50, 95% CI: 0.40–0.63, p
 0.0001]) (Table 1). Estimated PFS-2 rates at 12 and 24
months were higher in the pemetrexed and platinum
plus pembrolizumab across both subgroups (Table 1).
In the subgroup with less than or equal to 3 organ
systems with lesions, median PFS-2 was 22.5 months
with pemetrexed and platinum plus pembrolizumab and
10.5 months with pemetrexed and platinum plus placebo
(HR ¼ 0.43, 95% CI: 0.33–0.57, p  0.0001) (Table 1). In
the subgroup with greater than 3 organ systems with
lesions, median PFS-2 was 10.3 months with pemetrexed
and platinum plus pembrolizumab and 6.6 months with
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Figure 4. OS and PFS by severity score of patient-reported lung cancer-associated symptoms at baseline. Illustrated are
Kaplan-Meier estimates of OS and PFS in patients with symptom severity score less than or equal to the median (A and B) or
greater than the median (C and D). Tick marks indicate censoring of data at the last time the patient was known to be alive.
CI, conﬁdence interval; HR, hazard ratio; NSQ-NSCLC, nonsquamous NSCLC; OS, overall survival; Pem, pemetrexed; Pembro,
pembrolizumab; PFS, progression-free survival; Plat, platinum.

pemetrexed and platinum plus placebo (HR ¼ 0.60, 95%
CI: 0.45–0.80, p ¼ 0.0005) (Table 1). Estimated PFS-2
rates at 12 and 24 months were higher in the pemetrexed and platinum plus pembrolizumab arm across
both subgroups (Table 1).

In the subgroup with symptom severity score less
than or equal to median, median PFS-2 was 20.4 months
with pemetrexed and platinum plus pembrolizumab and
10.1 months with pemetrexed and platinum plus placebo
(HR ¼ 0.43, 95% CI: 0.31–0.59, p  0.0001) (Table 1). In

Figure 5. ORR and DoR by baseline tumor burden. Illustrated are the ORR (A) and median DoR (B) by tumor burden subgroups.
Responses are based on BICR assessment per RECIST version 1.1. In the M1a compared with M1b stage subgroups, 39.7% versus
23.3% of patients receiving pemetrexed and platinum plus pembrolizumab and 15.6% versus 6.5% of patients receiving
pemetrexed and platinum plus placebo had a DoR that lasted for 24 months. In the subgroup with number of organ systems
with lesions less than or equal to 3 compared with greater than 3, 33.7% versus 17.2% of patients receiving pemetrexed and
platinum plus pembrolizumab and 0.0% versus 11.6% of patients receiving pemetrexed and platinum plus placebo had a DoR
that lasted for 24 months. In the subgroup with symptom severity score less than or equal to the median compared with
greater than the median, 27.7% versus 29.2% of patients receiving pemetrexed and platinum plus pembrolizumab and 20.2%
versus 0.0% of patients receiving pemetrexed and platinum plus placebo had a DoR that lasted for 24 months. BICR, blinded
independent central review; DoR, duration of response; ORR, objective response rate; RECIST, Response Evaluation Criteria in
Solid Tumors.

patients with symptom severity score greater than median, median PFS-2 was 13.8 months with pemetrexed
and platinum plus pembrolizumab and 7.6 months with
pemetrexed and platinum plus placebo (HR ¼ 0.55, 95%
CI: 0.41–0.72, p  0.0001) (Table 1). Estimated PFS-2
rates at 12 and 24 months were higher in the pemetrexed and platinum plus pembrolizumab across both
subgroups (Table 1).
The PFS-2 beneﬁt with pemetrexed and platinum
plus pembrolizumab was maintained across all baseline
tumor burden subgroups regardless of PD-L1 expression
levels (Supplementary Table 8).
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71.1
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(0.41–0.72)
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Note: PFS-2 was deﬁned as the time from randomization to second/subsequent tumor progression on next-line treatment or death from any cause.
CI, conﬁdence interval; HR, hazard ratio; Pem, pemetrexed; Pembro, pembrolizumab; PFS, progression-free survival; Plat, platinum.
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89.7
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Events, %
Median, mo
Stratiﬁed HR
(CI 95%)
Estimated
rates, %
12 mo
24 mo

Pem/plat/ Pem/plat/
pembro
placebo
(n ¼ 187)
(n ¼ 82)
Pem/plat/ Pem/plat/
pembro
placebo
(n ¼ 170)
(n ¼ 88)
Pem/plat/ Pem/plat/
pembro
placebo
(n ¼ 285)
(n ¼ 53)
Pem/plat/
pembro
(n ¼ 123)

M1b

Table 1. PFS-2 by Baseline Tumor Burden

Pem/plat/
placebo
(n ¼ 152)

Pem/plat/
pembro
(n ¼ 235)

Pem/plat/
placebo
(n ¼ 118)

Pem/plat/
pembro
(n ¼ 175)

Median
3
M1a

>3

Symptom Severity Score
Organ Systems With Lesions
Staging

>Median

Pem/plat/
placebo
(n ¼ 97)
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To the best of our knowledge, this is the ﬁrst
manuscript reporting on the efﬁcacy of pemetrexed and
platinum plus pembrolizumab combination by baseline
tumor burden deﬁned using various criteria. The results
of this post hoc efﬁcacy analysis reveal the superior
clinical beneﬁt of pemetrexed and platinum plus pembrolizumab compared with pemetrexed and platinum
plus placebo across all baseline tumor burden subgroups. Notably, the treatment effect was maintained in
the low or high baseline tumor burden subgroups irrespectively of the criteria used for their characterization.
Importantly, the clinical beneﬁt with pemetrexed and
platinum plus pembrolizumab across baseline tumor
burden subgroups is comparable with the beneﬁt in the
overall study population from the updated analysis of
the KEYNOTE-189 study.13 Taken together, these results
underscore the efﬁcacy of pemetrexed and platinum plus
pembrolizumab combination across clinically distinct
patient populations.
We used three distinct variables to evaluate the
extent of tumor burden at baseline, and according to
these variables, we categorized the analysis population
in the following two main groups: patients with low
tumor burden (M1a stage, or 3 organ systems with
lesions, or symptom severity score  median) and patients with high tumor burden (M1b stage, or >3 organ
systems with lesions, or symptom severity score > median). The extent of metastatic involvement assessed by
M1a and M1b staging was used as a surrogate marker
for tumor burden given the difference in OS outcomes
between M1a and M1b stages.30 Previous results from
the KEYNOTE-189 study revealed consistent OS and PFS
beneﬁts with pemetrexed and platinum plus pembrolizumab in patients with M1a stage or M1b stage
disease.14 Here, we further reveal that in addition to OS
and PFS, pemetrexed and platinum plus pembrolizumab
signiﬁcantly prolonged PFS-2 in both M1a (p ¼ 0.0059)
and M1b (p  0.0001) subgroups with the same degree
of magnitude compared with pemetrexed and platinum
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plus placebo. Higher response rates and prolonged DoR
were also observed in both subgroups.
The extent of baseline tumor burden was also evaluated by the number of organ systems with metastatic
lesions. Notably, organ systems were included in the
assessment irrespectively of the number of lesions or the
size of the lesions present. Moreover, we did not exclude
organ systems on the basis of the size of the lesions
because small metastatic lesions can potentially have
biological and clinical signiﬁcance. The improvement in
OS, PFS, and PFS-2, including the proportion of patients
achieving an objective response, was greater with
pemetrexed and platinum plus pembrolizumab than
with pemetrexed and platinum plus placebo across both
organ systems with lesions subgroups. Nevertheless, the
treatment effect was slightly less pronounced in the
subgroup of greater than 3 organ systems with lesions
compared with the subgroup of less than or equal to 3
organ systems with lesions as illustrated by the higher
HRs for OS, PFS, and PFS-2.
Liver and brain metastases are poor prognostic factors in NSCLC26,30 and could have a negative impact on
treatment outcomes irrespectively of the extent of
baseline tumor burden. Consistent with this possibility,
in the study by Nagasaka et al.,31 although baseline tumor volume did not predict response to ICI therapy, the
presence of liver metastases was associated with worse
OS outcome. It is important to note that in our analysis,
the assessment of the number of organ systems with
lesions also included the liver and brain. Moreover, in a
previous analysis from the KEYNOTE-189 study,
although patients with liver or brain metastases had a
worse outcome compared with patients without liver or
brain metastases, the treatment effect of pemetrexed and
platinum plus pembrolizumab was similar among patients with or without liver or brain metastases.13
A novel aspect of this study is the inclusion of burden
of symptoms as an additional variable to assess baseline
tumor burden. We quantiﬁed burden of symptoms by
generating a symptom severity score of patient-reported
disease-related symptoms from the EORTC QLQ-LC13
questionnaire.29 The rationale for using burden of
symptoms as a surrogate marker of tumor burden is
supported by several lines of evidence. Patients with
metastatic lung cancer have a higher burden of symptoms than patients with other tumor types.32 Moreover,
high baseline burden of symptoms was reported to be an
independent negative predictor of OS in patients with
advanced NSCLC.32–34 In their study, Wang et al.34 reported that severity of baseline cough, a symptom
included in our assessment of symptom severity score,
was an independent risk for decreased OS. Consistent
with the ﬁndings obtained when using M staging or
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number of organ systems with lesions to characterize
baseline tumor burden, pemetrexed and platinum plus
pembrolizumab conferred a greater clinical beneﬁt than
pemetrexed and platinum plus placebo irrespectively of
the degree of the baseline symptom severity score.
Notably, the present analysis was not intended to
include any formal statistical comparison between high
and low tumor burden subgroups. Nevertheless, we
observed numerically higher OS in the low tumor burden
subgroups than in the high tumor burden subgroups
particularly when tumor burden was measured by organ
systems with lesions and symptom severity score. In
patients with low tumor burden, pemetrexed and platinum plus pembrolizumab lowered the risk of death
more than in patients with high tumor burden (M1a
stage: 46% versus M1b stage: 42%; 3 organ systems
with lesions: 51% versus >3: 33%; severity symptoms
score  median: 49% versus > median: 40%). The PFS
beneﬁt favoring pemetrexed and platinum plus pembrolizumab over pemetrexed and platinum plus placebo
also tended to be numerically higher in patients with low
tumor burden. Nevertheless, the observed OS and PFS
HRs stand out more in terms of numerical similarities
between high and low tumor burden subgroups; overall,
we therefore interpreted these results as revealing a
consistency of efﬁcacy between high and low tumor
burden subgroups.
Several studies have investigated the role of baseline
tumor burden as a prognostic factor in NSCLC. In a
pooled analysis from 1461 patients with NSCLC treated
with atezolizumab in the context of the OAK, BIRCH,
POPLAR, BIRCH, and FIR trials, a large baseline tumor
burden, measured as the sum of the longest diameters of
target lesions, was found to be an independent prognostic factor of worse OS and PFS.35 Similarly, in a
retrospective analysis of 83 patients with NSCLC
receiving ICI therapy, high tumor burden was a negative
prognostic factor for OS.20
The role of baseline tumor burden as a predictive
factor to response to treatment with ICIs has also been
investigated. In a recent exploratory analysis from the
IMpower 150 study, the clinical beneﬁt of atezolizumab
(Tecentriq) in combination with bevacizumab (Avastin)
and carboplatin plus paclitaxel (ABCP) was observed
across patients with high and low baseline tumor
burden, which was deﬁned as the sum of the longest
diameter of target lesions or the number of metastatic
sites at baseline versus bevacizumab (Avastin), carboplatin, and paclitaxel (BCP).36 Mixed results however
have been reported from several retrospective studies
using tumor size, tumor volume, or number of metastatic
lesions as surrogate markers for tumor burden. In a
recent retrospective real-world analysis of patients with
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metastatic NSCLC and high PD-L1 expression, baseline
tumor burden did not predict response to pembrolizumab.37 Similarly, Nagasaka et al.31 reported a lack
of association between baseline tumor volume and efﬁcacy outcomes in patients with NSCLC treated with
nivolumab or pembrolizumab. Conversely, in other
retrospective single-institution studies, high baseline
tumor burden was associated with decreased PFS and OS
beneﬁts to ICI monotherapy.18
The lack of consistency in the predicting value of
tumor burden to ICI therapy might be explained by the
different cutoff values used to deﬁne high versus low
tumor burden. Nevertheless, a favorable clinical
response to ICI therapy in small tumors compared with
large tumors was also reported in preclinical studies.38
Although the underlying biological basis is not well understood, differences in tumor immunity and immunosuppressive tumor microenvironment signals between
small tumors and large tumors may contribute to the
favorable response to treatment with ICIs found in small
tumors.39
When interpreting the results presented in this
manuscript, the following points should be taken
into consideration. The subgroup analyses across
PD-L1 expression levels comprised relatively small
sample sizes. Thus, although both PD-L1–negative
and PD-L1–positive patients across all baseline tumor burden subgroups beneﬁted from treatment
with pemetrexed and platinum plus pembrolizumab,
outcomes by PD-L1 expression revealed greater
variations consistent with the small sample sizes. In
addition, our study was not designed to investigate
the prognostic signiﬁcance of baseline tumor
burden; instead, the study investigated whether the
beneﬁt of pemetrexed and platinum plus pembrolizumab was maintained across patient populations
with
varying
degrees
of
disease
involvement at the time of presentation. Last, to
overcome potential biases owing to the lack of
standardization for deﬁnition of tumor burden, we
used three distinct variables to characterize baseline tumor burden thus allowing for a more
comprehensive assessment of total tumor burden at
baseline.
In conclusion, this is the ﬁrst systematic analysis
reporting on the efﬁcacy of pemetrexed and platinum
plus pembrolizumab across baseline tumor burden. The
results presented in here reveal the superior beneﬁt of
pemetrexed and platinum plus pembrolizumab irrespectively of the extent of baseline tumor burden and the
variables used to deﬁne it. These ﬁndings further substantiate the use of pemetrexed and platinum plus
pembrolizumab as the standard of care for the ﬁrst-line
treatment of patients with NSQ-NSCLC.
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